Jingxin Wang graduated with a B.S. in chemistry in 2006 from Peking University, China, where he performed research in computational chemistry and transition-metal catalysis (advisor: Zhi-Xiang Yu). He came to the United States for graduate training and completed his Ph.D. degree in chemistry in 2011 at the University of Maryland, under the guidance of Herman Sintim. In the Sintim lab, he was trained to synthesize novel molecules to combat bacterial antibiotic resistance. After graduation, he joined Jun Liu’s lab at Johns Hopkins University as a postdoc and conducted research on a novel drug modality called "rapafucin" to induce protein-protein interactions. In 2014, he started further chemical biology training in Peter Schultz's lab (co-advised by Kristen Johnson) at the Scripps Research Institute, where he is performing high-throughput screening, assay development, and target validation for novel viral and cancer immunotherapy, as well as mechanistic studies for molecules that modulate RNA splicing. He joined KU in 2019 as a tenure-track Assistant Professor an moved to the University of Chicago in 2024. His current research focuses on regulating RNA biochemistry and innate immunity in cells by small molecules.